

# FDAnews Guide to International Pharma Regulation: 2010 Edition

## Table of Contents

Appendices are noted with an asterisk\*

### Introduction

#### Advanced Therapy Medicinal Products

EMEA Designates Panel for Preliminary Review of Advanced Therapies, 2/09 . . . . .	3
Implementing ATMP Legislation Is EMEA Priority This Year, 3/09 . . . . .	4
<i>Work Programme for the European Medicines Agency 2009</i>	
UK Releases Temporary Road Map for Stem Cell R&D, 4/09 . . . . .	6
<i>Interim UK Regulatory Route Map for Stem Cell Research and Manufacture*</i>	
EMEA Advises Stakeholders on Submissions of Advanced Therapy Information, 5/09 . . . .	7
<i>Procedural Advice on the Evaluation of Advanced Therapy Medicinal Products *</i>	
MHRA Outlines Process for Using Advanced Therapies in Hospitals, 8/09 . . . . .	9
<i>Regulation on Advanced Therapy Medicinal Products*</i>	

#### Advertising/Marketing/Promotions

U.S. FDA to Crack Down on Advertising of Drugs in 2009, 1/09 . . . . .	13
EMEA Advises EEA Manufacturers on Marketing Requirements, 9/09 . . . . .	15

#### AIDS Drugs

WHO Recommends Countries Phase Out Use of AIDS Drug, 12/09 . . . . .	19
<i>WHO Public Assessment Report - Zerit, Powder for Oral Solution*</i>	

#### Anti-Fungal Drugs

EMEA Urges Sponsors to Investigate Activity Spectrum in Fungus Drugs, 8/09 . . . . .	23
<i>Guideline on the Clinical Evaluation Of Antifungal Agents for the Treatment and Prophylaxis of Invasive Fungal Disease*</i>	

## Anti-Malarials

- Reclassifications of Anti-Malarial Medicines Considered to Increase Access, 4/09 . . . . . 27  
*Accessibility of Malaria Prophylaxis Medicines\**

## Antibiotics

- Philippines Sets Conditions for Exemptions of Antibiotics from Batch Certification, 2/09 . . . 31

## Antitrust

- More Drugmakers Raided by EC in Antitrust Investigation, 12/09 . . . . . 35

## Antivirals

- EMA: Antivirals Can Be Taken by Pregnant Women in Pandemic, 5/09 . . . . . 39  
*Questions and Answers on the Use of Antiviral Medicines in Case of Novel Influenza A/H1N1 Pandemic\**

## Application, Approval, Authorization, Registration, Regulatory Review (non-U.S.)

- Consolidation of UK Medicines Act Under Way, 1/09 . . . . . 43  
*Concept Paper on MHRA Project to Consolidate and Review Medicines Legislation\**
- Tanzania Updates Guidelines on Drug Registration, Variations, 2/09 . . . . . 45  
*Tanzania - Guidelines on Submission of Documentation for Registration of Human Medicinal Products\**
- Netherlands Drug Authority Aims to Eliminate Backlog by 2011, 3/09 . . . . . 47  
*Broadening the Scope of Regulation: Beyond Gatekeeping\**
- South Africa Outlines Requirements for Post-Registration Amendments, 5/09 . . . . . 49
- China Outlines Regulatory Procedures for Drug Marketing Approval, 6/09 . . . . . 51  
*SFDA Provisions for Supervision of Drug Distribution\**
- MHLW Aims for Faster Approval of Unapproved Drugs, 6/09 . . . . . 52  
*MHLW Promotion of Measures to Provide Better Drugs Safely and Promptly\**
- EC Directive Simplifies Applications with Identical Amendments, 7/09 . . . . . 53  
*Directive Regarding Variations to the Terms of Marketing Authorisations for Medicinal Products\**
- Pakistan's Health Minister Halts New Drug Registration, 9/09 . . . . . 54
- India Centralizes Approval Process for Marketing Authorization, 10/09 . . . . . 55  
*The Modalities for Grant of WHO - GMP Certificate of Pharmaceutical Product\**
- EMA Amends Quality Review of Documents Templates, 10/09 . . . . . 56  
*Regulation on Advanced Therapy Medicinal Products\**
- EMA Marketing Authorizations to be Overseen by Three Units, 10/09 . . . . . 57
-

EMA Details Transfer Process for Marketing Authorizations, 11/09 .....	58
<i>EMA Human Medicines - Post-Authorisation Procedural Advice*</i>	
MHRA, EMA: Drugmakers Can Group Changes to Marketing Authorizations, 12/09 ...	59
<i>UK National MA Variations Guidance*</i>	
<i>Explanatory Note on Fees Payable to the European Medicines Agency*</i>	

## **Asthma Drugs**

EMA Scientific Committee Calls for New Asthma Drug Guidance, 11/09.....	63
<i>Concept Paper on the Need for Revision of the Guidance on the Clinical Development of Medicinal Products in the Treatment of Asthma*</i>	

## **Biologics**

CBER: Speed U.S. Biologic Review with Proper Application Format, 12/09.....	67
EMA Outlines Quality Requirements for Monoclonal Antibodies, 2/09.....	68
<i>Guideline on Development, Production, Characterization and Specifications for Monoclonal Antibodies and Related Products*</i>	

## **Biomarkers**

Genomic Biomarker Qualification is Subject of EMA Guidance, 7/09.....	71
<i>Genomic Biomarkers Related to Drug Response - Context, Structure and Format of Qualification Submissions*</i>	
EMA May Revise Guidelines on Biomarkers for Heart Drugs, 8/09.....	73
<i>Concept Paper on the Need to Update the Note For Guidance on Clinical Investigation of Medicinal Products in the Treatment of Lipid Disorders and Hypertension*</i>	

## **Biosimilars**

U.S. Bills Offer Competing Approaches to Regulation of Biosimilars, 4/09.....	77
<i>Act to Establish a Pathway for the Licensure of Biosimilar Biological Products*</i>	
<i>Act to Provide for the Licensing of Biosimilar and Biogeneric Biological Products*</i>	
EMA Gives Biosimilars Manufacturers Development Recommendations, 5/09.....	80
<i>Guideline on Non-Clinical and Clinical Development of Similar Biological Medicinal Products Containing Low-Molecular-Weight-Heparin*</i>	
Singapore Outlines Process to Register Biosimilars, 9/09 .....	81
<i>Guidance on Registration of Similar Biological Products in Singapore *</i>	

## **Cancer Drugs**

Study: Slow Approval Times in EU Mean Unequal Cancer Treatment, 2/09 .....	85
<i>Comparator Report - Cancer report EFPIA Final Summary Slides*</i>	
Health Canada Requires Updates to Labeling for TNF Blockers, 9/09 .....	87

## CDISC Standards

CDISC Studied by U.S. FDA to Streamline Data Analysis, 8/09 .....	91
---	----

## Clinical Trials

Guidance Requires Diabetes Drug Trials to Gather Data on Heart Risk, 1/09 .....	95
<i>Guidance - Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes*</i>	
France Issues Sponsor Guidance on Clinical Trial Changes, 1/09 .....	97
<i>Conduct of Clinical Trials on Medicinal Products for Human Use in France*</i>	
Guidance Clarifies Certification Requirements for Clinical Trial Sponsors, 2/09 .....	99
<i>Guidance - Certifications To Accompany Drug, Biological Product, and Device Applications or Submissions*</i>	
EMA to Increase Clinical Trial Inspections in Developing Nations, 3/09 .....	100
<i>EMA strategy paper - Acceptance of Clinical Trials Conducted in Third Countries*</i>	
EMA Final Guideline Outlines Requirements for Fixed-Combination Drugs, 3/09 .....	102
<i>Guideline on Clinical Development of Fixed Combination Medicinal Products*</i>	
ICH Clinical Trial Guidance Issued for Cancer Drugs, 3/09 .....	104
<i>Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals*</i>	
<i>Nonclinical Evaluation for Anticancer Pharmaceuticals*</i>	
Canada Releases Final Guidance on Preparation of Clinical Trial Applications, 4/09 ....	106
<i>Guidance: Clinical Trial Applications (CTAs) for Pharmaceuticals*</i>	
European Regulatory Barriers Inhibit Noncommercial Clinical Trials, 4/09 .....	107
<i>Investigator Driven Clinical Trials*</i>	
CHMP Advises Sponsors on Managing Missing Data in Clinical Studies, 6/09 .....	110
<i>Guideline on Clinical Investigation of Medicinal Products used in the Treatment of Osteoarthritis*</i>	
<i>Guideline on the Clinical Evaluation of Direct Acting Antiviral Agents Intended for Treatment of Chronic Hepatitis C*</i>	
<i>Guideline on Clinical Investigation of Medicinal Products for the Treatment of Ankylosing Spondylitis*</i>	
India Requires Drugmakers to Register Clinical Trials, 7/09 .....	112
Canada Tightens Reviews of Data From Foreign Trials, 7/09 .....	113
<i>Guideline for Good Clinical Practice*</i>	
EC Clarifies Study Standards in New Draft Guideline, 7/09 .....	114
<i>Detailed Guidance for the Request for Authorisation of a Clinical Trial on a Medicinal Product for Human Use to the Competent Authorities, Notification of Substantial Amendments and Declaration of the End of the Trial*</i>	

---

U.S. FDA May OK Adaptive Design in Confirmatory Trials, 7/09 .....	116
EC Clarifies Use of Comparators in Clinical Trials of Drugs, 8/09 .....	118
<i>EMA Guidance Documents Applying to Clinical Trials Q and A*</i>	
EMA, U.S. FDA Plan to Collaborate on Clinical Trial Inspections, 8/09 .....	119
NICE Database Allows Drugmakers to Track Cancer Research Needs, 11/09 .....	121
<i>CoCanCPG Database of Cancer Uncertainties</i>	
CHMP Advises Drug Sponsors on Foreign Study Data, 12/09 .....	122
<i>Reflection Paper on the Extrapolation of Results from Clinical Studies Conducted Outside the EU to the EU-Population*</i>	

## **Confidential Information Exchange**

Australian, European Regulatory Agencies Reach Information-Sharing Agreement, 6/09 .	125
Japan Signs Confidentiality Agreements with EC, Health Canada, 11/09 .....	126
<i>MHLW and PMDA Letter of Agreement*</i>	
<i>Health Canada - PMDA Confidentiality Agreement*</i>	

## **Contrast Agents**

EMA Warns Contrast Agents Associated with Kidney Risk, 12/09 .....	129
--	-----

## **Counterfeit Medical Products**

MHRA seeks Input on Strategies Against Counterfeiting, 1/09 .....	133
India Passes Sanction Legislation Against ‘Spurious’ Drugs, 1/09 .....	135
<i>The Drugs and Cosmetics Bill, 2008*</i>	
WHO's Role in Fighting Counterfeits Stalls on Definition, 2/09 .....	136
<i>Counterfeit Medical Products - Report by the WHO Secretariat*</i>	
<i>Follow-Up Action - Combating Counterfeit Medical Products*</i>	
MHRA Raid Seizes More Than \$700,000 in Counterfeit Drugs, 4/09 .....	138
EFPIA Launches New Pilot Program to Stop Counterfeiting, 11/09 .....	139

## **Cystic Fibrosis Drugs**

Cystic Fibrosis Drug Development is Subject of EMA Guideline, 12/09 .....	143
<i>Concept Paper on the Need for a Guideline on the Development of New Medicinal Products Intended for the Management and Treatment of Cystic Fibrosis*</i>	

## **Depression**

CHMP Plans to Issue Guidance on Resistant-Depression Drugs, 10/09 .....	147
<i>Concept Paper on the Need for Revision of Guidance on Clinical Investigation of Medicinal Products in the Treatment of Depression with Regard to Treatment Resistant Depression*</i>	

## **Direct-to-Consumer Communication**

- MHRA Seeks Comments on EC Proposal to Expand Prescribing Information, 6/09 . . . . . 151  
*Consultation on European Commission Proposals on Information to Patients for Prescription Medicines\**

## **Drug Substance Master Files**

- Japan Explains Registration Process for Drug Substance Master Files, 2/09. . . . . 155  
*Master File System for Drug Substances\**  
*Q&A on the Master File System - Part I\**  
*Q&A on the Master File System - Part II\**

## **Drug-Alcohol Interaction Testing**

- EMA Clarifies Rule on Testing for Drug-Alcohol Interaction, 5/09 . . . . . 159

## **Electronic Communication**

- EMA to Require Advice Requests to be Submitted Electronically, 9/09. . . . . 163  
EMA Encourages Industry Participation in Information Management Program, 10/09 . . 164  
*EMA Implementation of Product Information Management - Statement of Intent\**  
*Product Information Management Concepts\**

## **Electronic Data Exchange**

- Automated System to Transfer Data From MHRA to EMA, 5/09. . . . . 167

## **Electronic Submissions**

- Australia Issues Draft Guidance on eCTD Submissions, 2/09 . . . . . 171  
*TGA Guidance - Providing Regulatory Submissions for Prescription Medicines in Electronic Format (eCTD)\**  
PMDA Plans to Bring Drugs to Market More Quickly, 7/09. . . . . 173  
*Mid-term Plan of the Pharmaceuticals and Medical Devices Agency\**

## **Enforcement**

- Australian Bill Allows Temporary Suspension of Registered, Listed Drugs for Safety, 4/09. . . 177  
*Act to Amend the Therapeutic Goods Act 1989\**  
Enforcement Program Will Speed Warning Letter Process: U.S. FDA, 9/09 . . . . . 179  
*Review of Post-Inspection Responses\**  
U.S. FDA Provides 'Closeout Letters' to Warning Letter Recipients, 9/09 . . . . . 181  
*FDA Regulatory Procedures Manual - Advisory Actions\**  
EC Expands Anti-Competition Probe into Market Delays of Generics, 10/09 . . . . . 183
-

U.S. Government Pursues Fraud, Enforces Corrupt Practices Act, 10/09 .....	184
Experts: FCPA Violations Targeted by U.S. Justice Department, 12/09 .....	186

## **Fees**

Drugmakers Face Fee Increase from MHRA Next Year, 11/09 .....	189
<i>Medicines and Healthcare Products Regulatory Agency Regulatory Fees – Proposals for 1 April 2010*</i>	

## **Fibrinogen, Human**

EMA Issues Guideline on SmPC for Human Fibrinogen, 3/09 .....	193
<i>Guideline on Core SmPC for Human Fibrinogen Products*</i>	

## **Financial Disclosure**

Researcher Financial Disclosure Bill Stalls in U.S. Congress, 7/09 .....	197
<i>Act to Provide for Transparency in the Relationship Between Physicians and Manufacturers of Drugs, Devices, Biologicals, or Medical Supplies*</i>	

## **Generic Drugs**

Generic-Drug Industry Cites Reports in Call for Regulatory Reform, 1/09 .....	201
U.S. FDA Responds to Concerns about Authorized Generics Reporting, 3/09 .....	203
EC Report Finds Generic Drugs Take Too Long to Reach Market, 7/09 .....	204
<i>Executive Summary of the Pharmaceutical Sector Inquiry Report*</i>	
<i>Pharmaceutical Sector Inquiry Final Report*</i>	
<i>Pharmaceutical Sector Inquiry – Annexes*</i>	
U.S. FDA to Require NDA Reports to Include Authorized Generics, 8/09 .....	206
Generic Drug Price-Cut Initiative Launched by Alberta Government, 11/09 .....	207

## **Genotoxicity**

U.S. FDA Proposes Revising ICH Guidance on Genotoxicity, 11/09 .....	211
<i>Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use*</i>	

## **Good Manufacturing Practice**

Mexico Issues New GMP Requirements for Pharmaceutical Makers, 3/09 .....	215
EMA Plans to Update Its GMP Guide to Harmonize With Q10 Guideline, 5/09 .....	217
EC Reverses Course on Directive on GMPs for Drug Excipients, 6/09 .....	218

---

## Harmonization

Southeast Asian Regulatory Agencies to Harmonize GMPs, Inspections, 5/09 . . . . .	221
<i>ASEAN Mutual Recognition Arrangement for Good Manufacturing Practice Inspections of Manufacturers of Medicinal Products*</i>	
U.S. FDA Harmonizes Guidelines on Tablet Friability, Gel, 9/09 . . . . .	222
<i>Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Tablet Friability *</i>	
<i>Polyacrylamide Gel Electrophoresis General Chapter*</i>	

## Hemophilia Drugs

Hemophilia Drug Trials are Subject of CHMP Guidance, 8/09 . . . . .	225
<i>Guideline on the Clinical Investigation of Recombinant and Human Plasma-Derived Factor IX Products*</i>	
<i>Guideline on the Clinical Investigation of Recombinant and Human Plasma-Derived Factor VIII Products*</i>	

## HIV Drugs

Draft EMEA Guidance on HIV Drugs Draws Objections from Drugmakers, 6/09 . . . . .	229
<i>Overview of Comments Received on Draft Guideline on Carcinogenicity Evaluation of Medicinal Products for the Treatment of HIV Infection*</i>	

## Imports, Exports

Time Spent Reporting Is Under Review for Unapproved Drug Exports, 1/09 . . . . .	233
<i>FDA Comment Request - Export of Food and Drug Administration Regulated Products - Export Certificates*</i>	
Guidance Raises Bar for Laboratories that Test Drug Imports, 2/09 . . . . .	234
<i>Guidance - Submission of Laboratory Packages by Accredited Laboratories*</i>	
Seizures of Generic Drugs Protested by Health Groups, 3/09 . . . . .	235
<i>Seizures of Medicines as Goods in Transit to Developing Countries*</i>	
Critical Automated Information Sought for U.S. FDA Importation Decisions, 3/09 . . . . .	237
<i>Comment Request - Importer's Entry Notice*</i>	
U.S. FDA Will Allow Exporters to Self-Certify in Most Cases, 3/09 . . . . .	238
<i>Comment Request - Export of Food and Drug Administration Regulated Products - Export Certificates*</i>	
India Announces Key Drug Export Measures That Are Industry-Friendly, 4/09 . . . . .	239
<i>Strategy for Increasing Exports of Pharmaceutical Products*</i>	

---



India Offers Guidance on Imports of Pharmaceuticals for R&D Use, 11/09 . . . . .	240
European Drug Seizures Criticized by International Groups, 11/09. . . . .	241
<i>Trading Away Access to Medicines*</i>	

## **Influenza**

EU, U.S.: Pandemic Flu Drugs Need Separate Guidelines, 3/09 . . . . .	245
<i>EMA Guideline on Dossier Structure and Content for Pandemic Influenza Vaccine Marketing Authorization Application*</i>	
<i>FDA Guidance - Influenza - Developing Drugs for Treatment and/or Prophylaxis*</i>	

## **Innovative Medicines**

EMA May Provide Regulatory Advice to Drugmakers for Research Projects, 10/09 . . . .	249
--	-----

## **Inspections**

Three-Way GMP Inspection Collaboration Under Way, 2/09 . . . . .	253
<i>Update on a Pilot Project to Collaborate on International GMP Inspection Activities*</i>	
U.S. Legislation Aims to Globalize FDA Inspection Program, 2/09 . . . . .	254
U.S. FDA to Take Tougher Enforcement Stance in Plant Inspections Abroad, 5/09. . . . .	255
EC Outlines Inspection Procedures for GCPs at Research Sites, 6/09 . . . . .	256
<i>Guidance Document Containing the Common Provisions on the Conduct of GCP Inspections by Competent Authorities of the Different Member States*</i>	
Some Inspection Resources Shifted to Foreign Sites by U.S. FDA, 9/09 . . . . .	258
U.S. FDA Plans to Double Foreign GMP Inspections, 9/09. . . . .	260

## **Intellectual Property**

EC Litigation Plan Would Eliminate Multivalue Patent Litigation, 4/09 . . . . .	265
<i>Recommendation to Authorise the Commission to Open Negotiations for the Adoption of a Unified Patent Litigation System*</i>	

## **Labeling**

Brazil Updates Its Regulations for Drug Information Leaflets, 3/09 . . . . .	269
South Africa Toughens Standards for Package Insert Information, 10/09 . . . . .	270
Drugmakers Express Concern over U.S. FDA PCID Guidance, 10/09 . . . . .	271
<i>Guidance - Incorporation of Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting*</i>	

## Near-Infrared Spectroscopy

- EMA Issues New Draft Guidelines on Near-Infrared Spectroscopy, 3/09. . . . . 275  
*Guideline on the use of Near Infrared Spectroscopy by the Pharmaceutical Industry and Data Requirements for New Submissions and Variations\**

## Neonatal Drugs

- EMA Advises Drug Manufacturers on Developing Infant Products, 8/09. . . . . 279  
*Guideline on the Investigation of Medicinal Products in the Term and Preterm Neonate\**

## Orphan Medical Products

- EMA Seeks Input on Requirements for Orphan Medicine Designation, 2/09. . . . . 283

## OTC Drugs

- Canada Strengthens OTC Drug Labeling for Children's Cold Medicines, 1/09. . . . . 287  
*Nonprescription Oral Pediatric Cough and Cold Labelling Standard\**
- OTC Drug Labeling Guidance Clarifies Content, Format Requirements, 1/09. . . . . 289  
*Guidance - Labeling OTC Human Drug Products\**  
*Guidance - Questions and Answers Regarding the Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act: Revision 1\**
- Australia Plans to Overhaul OTC Drug Guidelines, 1/09. . . . . 291  
*Australian Regulatory Guidelines for OTC Medicines\**
- UK's MHRA Adds Addiction Warning to OTC Codeine Products, 9/09. . . . . 292
- Australia Allows Drugmakers to Monitor OTC Applications, 10/09. . . . . 293

## Patient-Reported Outcomes

- U.S. PRO Instrument Guidance Requires Patient Input, 12/09. . . . . 297  
*Guidance - Patient-Reported Outcome Measures - Use in Medical Product Development to Support Labeling Claims\**  
*Guidance - Target Product Profile — A Strategic Development Process Tool\**

## Pediatric Drugs

- EMA Outlines Application Process for Pediatric Product Investigations, 6/09. . . . . 301
- EMA Outlines Pediatric Plans for Allergen Products, 12/09. . . . . 302  
*Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases\**

## **Pharmacovigilance**

EMA Outlines Vaccine Measures for Pharmacovigilance, 9/09 .....	307
<i>Guidelines on Pharmacovigilance for Medicinal Products for Human Use*</i>	
<i>Guideline on the Conduct of Pharmacovigilance for Vaccines for Pre- and Post-Exposure Prophylaxis Against Infectious Diseases*</i>	

## **Postmarket Reporting, Surveillance**

Industry Asked to Comment on Sentinel System For Postmarketing Surveillance, 4/09 ..	311
<i>The Critical Path Initiative*</i>	
Japan May Require Drugmakers to Conduct Postmarketing Surveys in Some Cases, 11/09 ..	312
Postmarket Adverse Event Reporting Explained in Eudra Vigilance Guidance, 12/09 ....	313
<i>Note for Guidance Eudravigilance Human – Processing of Safety Messages and Individual Case Safety Reports*</i>	

## **Pricing, Reimbursement**

EC Is Considering Database of Prices for Medicines, 3/09 .....	317
<i>Call for Proposals - Development of a Database on the Pricing of Medicinal Products in the EU*</i>	
NHS Will Slice \$800 Million from Drug Prices, Curb Sales Starting This Year, 5/09 ....	318
Philippines Imposes Price Cuts on Brand Drugs, 9/09 .....	319

## **Pulmonary Hypertension Drugs**

EMA Gives Clinical Requirements for Pulmonary Hypertension Drugs, 12/09 .....	323
<i>Guideline on the Clinical Investigations of Medicinal Products for the Treatment of Pulmonary Arterial Hypertension*</i>	

## **Quality**

NICE Forms Committee to Review, Recommend QOF Indicators, 6/09 .....	327
UK's NICE to Develop Standards for Quality, Cost-Effectiveness, 8/09 .....	328
<i>High Quality Care for All*</i>	

## **Radiopharmaceuticals**

Australia Adopts GMP Guidelines on Radiopharmaceuticals, 9/09 .....	331
---	-----

## **Recalls**

EMA Revises Rapid Alert System to Include APIs, Drug Recalls, 7/09 .....	335
<i>Procedure for Handling Rapid Alerts Arising from Quality Defects*</i>	

---

## Reference Products

- South Africa Releases Guidelines for Reference Products, 7/09 ..... 339  
*Guidelines for Registration of Medicines\**

## Regulatory Role of Health Care Providers

- Industry Criticizes EMEA Plan to Include Input from Providers in Committee Decisions,  
5/09 ..... 343  
*HCP WG Final Recommendations and Proposals for Action\**

## Reimportation

- U.S. Senate Has Plans to Consider Drug Reimport Bill This Year, 6/09 ..... 347

## Repurchasing of Drugs

- Ontario Pursues Legal Measures against Drug Repurchasing Plan, 5/09 ..... 351

## Safety, Risk Management

- EC Adopts Comprehensive Package on Pharmaceuticals, 1/09 ..... 355  
*EC Summary of Measures Protecting the Medicines Supply Chain\**  
*Directive of the European Parliament Regarding Prevention of the Falsified Medicinal  
Products\**
- U.S. FDA Establishes Latin American Presence with Costa Rica Office, 1/09 ..... 357
- China-U.S. Agreement Signals More Cooperation on Safety, Quality of Drugs, 4/09 .... 358
- PMDA Planning to Increase International Presence, 6/09 ..... 359  
*PMDA International Strategic Plan\**

## Scientific Advice Program

- Drugmakers to Get Parallel Advice from EMEA, U.S. FDA, 10/09 ..... 363

## Subvisible Particle Testing

- ICH Guidance Plans to Coordinate Particle Testing for Drugmakers, 2/09 ..... 367  
*Test for Particulate Contamination: Sub-Visible Particles\**

## Supplies, Suppliers

- U.S. Considers Pilot Program for Drug, API Importation, 2/09 ..... 371  
*FDA Secure Supply Chain Pilot Program\**
- U.S. FDA Tells Manufacturers How to Protect Supply Chains, 10/09 ..... 372
- U.S. FDA Warns Manufacturers about Shadow Factories, 11/09 ..... 373
-

## **Technology Assessment**

- UK Initiates New Appraisal Steps to Speed Access to Treatments, 3/09 . . . . . 377  
*Topic Selection Process for Technology Appraisals\**

## **Training**

- EMA Training Office Could Ease Regulatory Process for Drugmakers, 8/09 . . . . . 381  
*Draft Strategy for Regulatory and Scientific Training within the European Regulatory Network\**

## **Transparency**

- EMA to Increase Transparency in Drug Approval Process, 7/09 . . . . . 385  
*The EMA Transparency Policy Draft for Public Consultation\**
- U.S. FDA Considers Disclosing Data from Pending, Withdrawn NDAs, 11/09 . . . . . 386

## **Treatment Guidelines**

- National UK Guideline-Development Institution Created from Merger of Four Centers, 5/09 . . . . . 389
- NICE Guideline Increases Treatments for Type 2 Diabetes, 6/09 . . . . . 390  
*NICE Guideline for Management of Type 2 Diabetes\**

## **Treatment-Resistant Infections**

- EMA Plans Development Guidance for Treatment-Resistant Infections, 10/09 . . . . . 393  
*The Bacterial Challenge - Time to React\**

## **Vaccines**

- EMA Urges Manufacturers to Use Mock-Up Vaccines, 6/09 . . . . . 397  
*Emea Pandemic Influenza Crisis Management Plan for the Evaluation And Maintenance of Pandemic Influenza Vaccines and Antivirals\**

- Index by Country/Regulator . . . . . 399**

- Index by Issue Date. . . . . 411**
-